#Japan #Chuo #FonesLife #BioTools #SomaScan

FonesLife Introduces the 2026 Japan Proteomics Research Grant Award

FonesLife Corporation, headquartered in Chuo, Tokyo and led by CEO Naoto Egawa, has announced the commencement of its first open research grant program, the 2026 Japan Proteomics Research Grant Award. This initiative, in collaboration with the American company Standard BioTools™, is set to launch on January 13, 2026, aimed at supporting the activities of researchers across Japan.

Program Overview

FonesLife is known for its advanced protein measurement services, including the SomaScan™ Assay and KREX™ protein microarray, which allow researchers to analyze around 11,000 types of proteins simultaneously. This enables efficient biomarker discovery, providing high-quality proteomic data as a tool for pilot data creation essential for future grant applications.

The SomaScan Research Grant Award will select two winners each from the SomaScan and KREX categories, totaling four recipients. Each winner will receive access to these cutting-edge services, allowing for the analysis of up to 40 samples, yielding:
1. High-plex proteomic data from the SomaScan 11K Assay
2. Antibody profiling data from the KREX protein microarray

Furthermore, recipients will also benefit from technical support provided by Standard BioTools.

Eligibility and Application Details

For information regarding application requirements, selection criteria, and notification of results, interested parties can visit the official application page here.

Selection Schedule:

About FonesLife

FonesLife operates as a subsidiary fully funded by NEC Solution Innovators, which handles NEC Group's healthcare business. By utilizing the blood protein measurement technologies developed by Standard BioTools and leveraging NEC's expertise in big data analysis and advanced ICT, FonesLife aims to forecast future disease risks, including dementia, and propose personalized lifestyle improvement strategies.

Through services like the SomaScan™ Assay, which can analyze nearly 11,000 proteins in one go and the KREX™ protein microarray, which can measure about 1,800 antibodies concurrently, FonesLife plays a crucial role in advancing proteomic analysis.
More information can be found at the following links:

• - SomaScan™ Assay
• - KREX™ protein microarray

Fostering a Healthy Work Environment

FonesLife proudly promotes health management within the company, reflecting a commitment to strategic health management practices. The company has declared its dedication towards extending employee health span, proposing to align retirement ages with Japan's average healthy lifespan (75 years as of 2025). This initiative further enables them to adjust retirement age in conjunction with health longevity.

In response to the longevity society, FonesLife aims for a vision where everyone can live authentically. The company has adopted flexible work arrangements, including remote work, full flex hours, workations, and, under certain conditions, side jobs, enabling employees to work in ways that best suit their individual needs.

All company names and product names mentioned herein are trademarks or registered trademarks of their respective owners.

For further inquiries from customers, please visit our contact page.

For press inquiries, please contact: FonesLife Public Relations at [email protected].